Study Assessing Efficacy of ZARNESTRA™ Combined With Tamoxifen in Patients With Advanced or Metastatic Breast Cancer

This study has been terminated.
Janssen-Cilag Ltd.
Information provided by:
Institut Claudius Regaud Identifier:
First received: September 13, 2005
Last updated: November 10, 2006
Last verified: November 2006

The purpose of this study is to evaluate the objective response rate when ZARNESTRA is added to treatment with tamoxifen

Condition Intervention Phase
Breast Neoplasms
Drug: Tamoxifen
Drug: Zarnestra
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Open, Single-Arm Phase II Study Assessing Efficacy of ZARNESTRA™ Combined With Tamoxifen in Patients With Advanced or Metastatic Breast Cancer Expressing the Estrogen and/or Progesterone Receptor

Resource links provided by NLM:

Further study details as provided by Institut Claudius Regaud:

Primary Outcome Measures:
  • To evaluate the objective response rate when ZARNESTRA is added to administration of tamoxifen in patients suffering from metastatic or advanced inoperable breast cancer, who are progressing on tamoxifen treatment

Secondary Outcome Measures:
  • To evaluate the time to progression
  • To evaluate the clinical benefit (response + stable disease at 6 months)
  • To evaluate the safety of the combination ZARNESTRA and tamoxifen
  • To evaluate a possible pharmacokinetic interaction between ZARNESTRA and tamoxifen
  • To evaluate the biological predictive and prognostic factors of a response

Estimated Enrollment: 40
Study Start Date: August 2003
Estimated Study Completion Date: August 2008

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically proven, metastatic or locally advanced inoperable breast cancer
  • Tumor considered potentially hormone-sensitive, i.e. presence by IHC of hormone receptors for estrogens (ER+ for more than 10% of cells) and/or progesterone (Pg+ for more than 10% of cells) or both. This expression may have been detected on the primary tumor or at a metastatic site. The method used will be reassessed by IHC if it involves a radioligand technique whenever it is possible to obtain histological material.
  • Progressing on treatment with tamoxifen, given either as adjuvant treatment or for advanced/metastatic breast cancer. Any previous treatment with a steroidal or nonsteroidal antiaromatase in a neo-adjuvant, adjuvant or metastatic situation is permitted. Likewise, any previous treatment with chemotherapy and/or herceptin in a nonmetastatic situation is permitted.
  • Post-menopausal patients
  • Age > 18 years
  • At least one measurable lesion according to the Response Evaluation Criteria for Solid Tumors (RECIST) criteria; for patients who only have bone metastases, an evaluable non-irradiated lytic lesion is required
  • Performance Status (WHO): PS ≤ 2 (Appendix 1).
  • Laboratory tests in accordance with the following criteria:

Neutrophils ≥ 2x109/l,Platelets ≥ 100x109/l,Hemoglobin ≥ 10 g/dl, ASAT, ALAT ≤ 2.5 N , or < 5 N when liver metastasis,bilirubin ≤ 1.5 N creatinin ≤ 1.5 N

  • Signed, written consent before any study-related procedure

Exclusion Criteria:

  • Men
  • Pre-menopausal patients who are not receiving concurrent LHRH agonist therapy
  • ER- and PR-negative patients
  • Contraindication to antiestrogens (thromboembolic risk) or ZARNESTRA
  • Non metastatic tumor susceptible to management by radiotherapeutic and/or surgical means
  • T4d inflammatory tumor (PEV 2 or 3).
  • Short-term, life-threatening lesions: hepatic invasion > 1/3 of liver volume, pulmonary lymphangitis, uncontrolled cerebral metastases, carcinomatous meningitis
  • Sensory neuropathy > or = grade 1 (WHO)
  • Previous history of uncontrolled cancers or controlled for less than 5 years, except basal cell skin cancers and in situ cancers of the cervix.
  • Chronic diseases (somatic or psychiatric) with a poor prognosis
  • subjects with enzyme-inducing anti-convulsants (e.g., phenytoin, phenobarbital, carbamazepine) : this treatment is not permitted while taking ZARNESTRA
  • Patients who, for family, social, geographic or psychological reasons, could not be followed up correctly.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00210028

Institut Bergonie
Bordeaux, France
Institut Val d'Aurelle_ Paul Lamarque
Montpellier, France
Institut Claudius Regaud
Toulouse, France
Sponsors and Collaborators
Institut Claudius Regaud
Janssen-Cilag Ltd.
Principal Investigator: Henri Roché, Pr Institut Claudius Regaud
  More Information

No publications provided Identifier: NCT00210028     History of Changes
Other Study ID Numbers: 03 SEIN 04
Study First Received: September 13, 2005
Last Updated: November 10, 2006
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Keywords provided by Institut Claudius Regaud:
Breast Neoplasms
estrogen receptor
progesterone receptor

Additional relevant MeSH terms:
Breast Neoplasms
Breast Diseases
Neoplasms by Site
Skin Diseases
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Bone Density Conservation Agents
Estrogen Antagonists
Estrogen Receptor Modulators
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Selective Estrogen Receptor Modulators
Therapeutic Uses processed this record on October 08, 2015